Meeting
2020 Genitourinary Cancers Symposium
Survival outcomes associated with different palliative systemic therapies (PSTs) in patients with metastatic bladder cancer (mBC).
Authors
Saba Vafaei-Nodeh
BC Cancer Agency, Vancouver, BC, Canada
Saba Vafaei-Nodeh , Arshia Beigi , Longlong Huang , Gillian Mimmack , Shaun Zheng Sun , Jenny J. Ko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 450)
Abstract #
450
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Gemcitabine and carboplatin versus gemcitabine and paclitaxel chemotherapy in cisplatin ineligible advanced-stage urothelial cancers: A prospective randomized control study.
First Author: Parmod Kumar
Poster
2021 ASCO Annual Meeting
Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.
First Author: Majd Issa
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron
Poster
2018 Genitourinary Cancers Symposium
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
First Author: Michaela Ann Dinan